The 2019-nCoV viral infection causes clusters of severe respiratory illness such as an acute respiratory distress syndrome (ARDS) similar to that caused by SARS-CoV (severe acute respiratory syndrome coronavirus) (Huang *et al.*[@CR5]). Both 2019-nCoV and SARS-CoV use the same receptor, ACE2 (angiotensin converting enzyme 2), to infect cells (Li *et al.*[@CR13]; Zhou *et al.*[@CR25]). ACE2 is one of the central enzymes in the renin--angiotensin system (RAS) (Donoghue *et al.*[@CR1]; Imai *et al.*[@CR8]; Tipnis *et al.*[@CR22]) that regulates blood pressure, fluid and electrolyte balance, and systemic vascular resistance (Paul *et al.*[@CR18]; Zimmerman and Dunham [@CR26]).

In the lungs, activation of local pulmonary RAS can affect the pathogenesis of lung injury via multiple mechanisms, such as an increase in vascular permeability and alterations of alveolar epithelial cells (Kuba *et al.*[@CR11]; Specks *et al.*[@CR21]). Activation of pulmonary RAS involves renin, the initial enzyme of the RAS activation cascade (Fig. [1](#Fig1){ref-type="fig"}). Renin cleaves angiotensinogen, a globular protein, to generate angiotensin I (Ang I, a decapeptide hormone). The angiotensin-converting enzyme (ACE) then converts Ang I to angiotensin II (Ang II, an octapeptide hormone). Ang II exerts vasoactive effects through binding to its receptors, the angiotensin II type I (AT1) and type II (AT2) receptors.Fig. 1Potential therapeutics for 2019-nCoV-induced lung injury based on balancing the renin--angiotensin system (RAS). Activation of the RAS cascade involves Renin cleaves angiotensinogen to generate Ang I, which is then converted to Ang II by ACE. Ang II binds to its receptors (AT1 and AT2) to exert local and systemic effects such as vasoconstriction and promotion of the release of aldosterone. ACE2 functions as a counter-regulatory enzyme for balancing responses initiated from ACE. ACE2 hydrolyses Ang I and Ang II to generate Ang-(1--9) and Ang-(1--7). Ang-(1--7) binding to the MAS receptor antagonizes Ang II-mediated actions. SARS-CoV and 2019-nCoV use ACE2 as the entry receptor. Inhibition of ACE2 expression or downregulation of surface ACE2 by these coronaviruses may disrupt function balances between ACE/ACE2, which may be alleviated by different approaches (from **A** to **D**).

ACE2 is a homologue of ACE and plays a pivotal role in balancing responses initiated from ACE (Donoghue *et al.*[@CR1]; Imai *et al.*[@CR8]; Tipnis *et al.*[@CR22]). ACE2 hydrolyses Ang I to generate Ang-(1--9). ACE2 also hydrolyses Ang II to generate Ang-(1--7), which binds to the G-protein coupled receptor MAS (Reudelhuber [@CR19]; Santos *et al.*[@CR20]) to antagonize many of the Ang II-mediated effects. Overall, ACE2 functions as a counter-regulatory enzyme by decreasing local Ang II concentrations.

In the lungs, RAS activity, ACE, and Ang II are intrinsically high, and ACE2 activities are also highly elevated to regulate the balance of Ang II/Ang-(1--7) levels (Kuba *et al.*[@CR11]; Specks *et al.*[@CR21]). High levels of Ang II can lead to increases in vascular permeability and pulmonary oedema (Fyhrquist and Saijonmaa [@CR2]; Marshall [@CR16]; Marshall *et al.*[@CR17]). In mouse models of acute respiratory distress syndrome, ACE2 knockout mice displayed more severe symptoms, while overexpression of ACE2 had some protective effects (Imai *et al.*[@CR6]). In SARS-CoV infection of mice, both viral replication and the viral spike protein alone have been shown to selectively reduce ACE2 but not ACE expression (Kuba *et al.*[@CR10]). In addition, SARS-CoV also induces rapid downregulation of ACE2 from the cell surface (Glowacka *et al.*[@CR3]; Wang *et al.*[@CR23]) and the release of catalytically active ACE2 ectodomains (Haga *et al.*[@CR4]; Jia *et al.*[@CR9]; Lambert *et al.*[@CR12]). These results suggest that the physiological balance between ACE/ACE2 and Ang II/Ang-(1--7) is likely disrupted by SARS-CoV viral infection. This virus-mediated effect likely has a pathogenic role in lung injury (Imai *et al.*[@CR7]; Kuba *et al.*[@CR11]; Yamamoto *et al.*[@CR24]). Indeed, injection of SARS-CoV spike protein into mice led to a significant increase in Ang II levels in the lung tissue and exacerbated acid-induced acute lung injury (Kuba *et al.*[@CR10]). Results from these previous animal studies suggested a possible mechanism of how SARS-CoV infection may cause severe lung failure, which is likely mediated through high levels of Ang II resulting from the inhibition of ACE2 by the viral spike protein. Given that the spike protein of 2019-nCoV interacts with ACE2 as does the spike protein of SARS-CoV, it is possible that the pathogenic mechanism may be shared between these two viruses. Based on this assumption, compensation of ACE2 and balancing ACE/ACE2 function may be a way to alleviate virus-induced severe lung injury.

There are several potential therapeutic approaches that may be tested or developed (Fig. [1](#Fig1){ref-type="fig"}). First, therapies to increase ACE2 expression may be developed in the future, through direct injection of recombinant ACE2 protein, which has been shown to protect mice from severe acute lung injury (Imai *et al.*[@CR6]), and by delivering therapeutic vectors expressing high levels of ACE2 directly into lung tissues to overcome virus-induced ACE2 deficiency. Second, certain ACE inhibitors such as lisinopril may be used to balance the ACE/ACE2 function. In addition, therapeutic Ang-(1--7) heptapeptide may be delivered to activate its receptor MAS and to counteract the activities of Ang II. Furthermore, drugs blocking Ang II receptors may also be tested. In particular, the type I, but not type II, Ang II receptor has been shown to promote disease pathogenesis by inducing lung oedemas and impairing lung function (Imai *et al.*[@CR6]). Thus, a type I Ang II receptor blocker such as losartan could be tested for alleviating 2019-nCoV-induced lung injury.

In sum, at present, there are no effective drugs for the treatment of 2019-nCoV-induced lung injury, which can often lead to lethal lung failure in patients. This perspective is intended to stimulate discussions about possible pathogenic mechanisms, based on the interaction of the virus with its receptor ACE2, so that rational therapies can be developed. Although ACE is regarded as the primary Ang II-converting enzyme, another enzyme, chymase, is also involved in converting Ang II in certain pathological conditions that may need attention (Fyhrquist and Saijonmaa [@CR2]; Lindberg *et al.*[@CR14]). In addition, coronavirus pathogenesis is a highly complex process (Lo *et al.*[@CR15]), and much of the needed detail in host--pathogen interaction in 2019-nCoV infection awaits investigation. It also remains to be clinically tested whether some of these potential treatments, as proposed here, can be effective or beneficial in the management of 2019-nCoV-induced lung injury.
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